Skip to Content
MilliporeSigma
All Photos(1)

Documents

M-136

Supelco

Methotrexate solution

1.0 mg/mL in methanol with 0.1N NaOH, ampule of 1 mL, certified reference material, Cerilliant®

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C20H22N8O5
CAS Number:
59-05-2
Molecular Weight:
454.44
MDL number:
MFCD00064369
UNSPSC Code:
41116107
PubChem Substance ID:
329817872
NACRES:
NA.24

grade

certified reference material

form

liquid

feature

Snap-N-Spike®/Snap-N-Shoot®

packaging

ampule of 1 mL

manufacturer/tradename

Cerilliant®

concentration

1.0 mg/mL in methanol with 0.1N NaOH

technique(s)

gas chromatography (GC): suitable
liquid chromatography (LC): suitable

application(s)

pharmaceutical (small molecule)

format

single component solution

Storage temp.

−20°C

SMILES string

O=C(C1=CC=C(N(C)CC2=NC3=C(N=C2)N=C(N)N=C3N)C=C1)NC(C(O)=O)CCC(O)=O

InChI

1S/C20H22N8O5/c1-28(9-11-8-23-17-15(24-11)16(21)26-20(22)27-17)12-4-2-10(3-5-12)18(31)25-13(19(32)33)6-7-14(29)30/h2-5,8,13H,6-7,9H2,1H3,(H,25,31)(H,29,30)(H,32,33)(H4,21,22,23,26,27)

InChI key

FBOZXECLQNJBKD-UHFFFAOYSA-N

Related Categories

General description

A Certified Spiking Solution® for use in therapeutic drug monitoring (TDM) analyses by HPLC or LC/MS. Used in the treatment of cancer and autoimmune diseases, methotrexate is an antimetabolite and antifolate drug monitored by clinical labs to ensure patients remain within the drug′s therapeutic range. The Snap-N-Spike® format allows laboratories to eliminate weighing operations of hazardous substances such as methotrexate, significantly reducing occupational exposure hazards related to handling of acutely toxic powders, and provides the ability to spike into their matrix of choice just before use.

Application


  • Pharmacokinetic analysis: Methotrexate solution is employed in advanced pharmacokinetic studies using UV-Vis spectrophotometric and colorimetric methods. This application facilitates precise quantification in plasma and tissue, crucial for evaluating drug distribution and effectiveness in cancer treatments (Febrianti et al., 2024).

  • Toxicity and safety monitoring: Observational studies utilize Methotrexate solution to investigate root causes of medication errors and manage toxicity in elderly patients. This research supports safer clinical practices by identifying risk factors and improving patient safety protocols (Bisht et al., 2024).

  • Nephrotoxicity prevention: Research on Methotrexate solution examines hydration strategies to mitigate nephrotoxicity, enhancing therapeutic outcomes. This study is pivotal in optimizing Methotrexate use in clinical settings, ensuring higher safety and efficacy for patients undergoing chemotherapy (Hasanpour et al., 2024).


Legal Information

CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany
CERTIFIED SPIKING SOLUTION is a registered trademark of Cerilliant Corporation
Snap-N-Shoot is a registered trademark of Cerilliant Corporation
Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany

signalword

Danger

Hazard Classifications

Acute Tox. 3 Dermal - Acute Tox. 3 Inhalation - Acute Tox. 3 Oral - Flam. Liq. 2 - Met. Corr. 1 - STOT SE 1

target_organs

Eyes,Central nervous system

Storage Class

3 - Flammable liquids

wgk_germany

WGK 2

flash_point_f

51.8 °F - closed cup

flash_point_c

11 °C - closed cup

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Joshua F Baker et al.
Annals of the rheumatic diseases, 73(11), 1968-1974 (2013-08-02)
To determine if early MRI measures predict X-ray progression at 1 and 2 years in a large RA trial cohort. This study included 256 methotrexate (MTX)-naïve RA patients from a randomised placebo-controlled trial of golimumab (GO-BEFORE). MRIs of wrist and 2nd-5th
J Westra et al.
Clinical and experimental immunology, 178(1), 40-47 (2014-06-04)
Rituximab (RTX) treatment in rheumatoid arthritis (RA) patients severely hampers humoral response after influenza vaccination as determined by haemagglutination inhibition assay (HI). It is not known whether HI reflects both immunoglobulin (Ig)M and IgG (subclass) influenza response, and whether IgM
Daniel H Solomon et al.
The American journal of medicine, 126(8), 730-730 (2013-07-28)
Elevated tumor necrosis factor (TNF)-α likely contributes to the excess cardiovascular risk observed in rheumatoid arthritis. We compared the cardiovascular risk in rheumatoid arthritis patients starting a TNF-α blocking agent versus a nonbiologic disease-modifying antirheumatic drug (nbDMARD). Subjects with rheumatoid
Richard Conway et al.
Arthritis & rheumatology (Hoboken, N.J.), 66(4), 803-812 (2014-04-24)
Methotrexate has shown efficacy for the treatment of several diseases, especially rheumatoid arthritis (RA). Methotrexate has also been implicated as a causative agent in interstitial lung disease. Patients with RA may develop pulmonary manifestations of their disease and are at
Davide Soldini et al.
Journal of clinical pathology, 67(7), 582-586 (2014-04-12)
To investigate whether drugs others than mycophenolic acid and ipilimumab might cause graft-versus-host-like apoptotic enteropathy, the clinicopathological findings in four patients were examined who had developed watery diarrhoea and apoptotic enteropathy (three cases from colon and one case from ileal
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service